A Phase 3 interventional study of Gemcitabine (Chemotherapy) and Paclitaxel (Chemotherapy) in Ovarian Cancer, sponsored by Hoffmann-La Roche. Completed at 68 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-23.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing gemcitabine in Ovarian Neoplasms — none open to participants now, 2 under way, 1 of them phase 3. Gemcitabine · Ovarian Neoplasms.
Among the 40 studies testing gemcitabine in Ovarian Neoplasms, this one is the 5th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2012, is one of 7 in phase 3, and was the 36th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →None of the 40 studies testing gemcitabine in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 25 · Phase 3 7
First in 1998; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 208 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 39 across the 34 interventional studies. Of the 34 that completed or were terminated, 12 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 40 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
35 studies in Ovarian Neoplasms by Hoffmann-La Roche: none open now, 3 under way, none of them phase 3. Of 31 finished, 14 (45%) have results posted.
Among the 35 studies in Ovarian Neoplasms by Hoffmann-La Roche, this one is the 7th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2012, is one of 7 in phase 3, and was the 17th registered.
Hoffmann-La Roche’s Ovarian Neoplasms studies by the year they started, since 2001.
1 of the studies testing gemcitabine in Ovarian Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01970722City of Hope Medical CenterSurgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | 2027-01-05 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing gemcitabine in Ovarian Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 35 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
This two-part, multicenter study will evaluate the safety, tolerability and efficacy of pertuzumab in combination with standard chemotherapy in women with recurrent platinum-resistant epithelial ovarian cancer. In the non-randomized Part 1 safety run-in, participants will receive pertuzumab plus either topotecan or paclitaxel. In the randomized, double-blind Part 2 of the study, participants will receive either pertuzumab or placebo in combination with chemotherapy (topotecan, paclitaxel, or gemcitabine).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received pertuzumab and topotecan in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
Drug: Paclitaxel (Chemotherapy) · Drug: Pertuzumab · Drug: Topotecan (Chemotherapy)
Participants received pertuzumab and paclitaxel in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
Drug: Paclitaxel (Chemotherapy) · Drug: Pertuzumab · Drug: Placebo
Participants received pertuzumab and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
Drug: Gemcitabine (Chemotherapy) · Drug: Paclitaxel (Chemotherapy) · Drug: Pertuzumab · Drug: Topotecan (Chemotherapy)
Participants received pertuzumab matching placebo and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
Drug: Gemcitabine (Chemotherapy) · Drug: Paclitaxel (Chemotherapy) · Drug: Placebo · Drug: Topotecan (Chemotherapy)
Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.
Participants administered paclitaxel at a dosage of 80 mg/m\^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.
Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
Participants administered topotecan at a dosage of 1.25 mg/m\^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.
Part 1: Percentage of Participants With Adverse Events (AEs)
An AE can be any unfavorable and unintended sign (including an abnormality laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Approximately 28 months (assessed at screening, baseline until 28 days after the last dose of study treatment)
Part 2: Progression Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Including Malignant Bowel Obstruction (MBO)
PFS (IRC-Assessed) was defined as the time from randomization into Part 2 of the trial until progressive disease (PD), MBO or death from any cause, whichever occurred first per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. PD could base on symptom deterioration or was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions.
Time frame: Approximately 44 months (assessed at screening and every 9 weeks from randomization until disease progression)
Part 1- Objective Response Rate (ORR)
ORR was defined as the number of participants with best overall response (BOR) of complete response (CR) or partial response (PR) recorded from the start of treatment, until the end of treatment. BOR documented as confirmed CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeter (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Approximately 28 months (assessed at baseline and every 9 weeks from randomization until disease progression)
Part 2- Objective Response Rate (ORR)
ORR was defined as the number of participants with BOR of CR or PR recorded from the start of treatment, until the end of treatment. BOR documented as confirmed CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeter (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Approximately 44 months (assessed at screening and every 9 weeks from randomization until disease progression)
Part 1: PFS Assessed by the Investigator
PFS as assessed by Investigator was defined as the time from first dose of pertuzumab or chemotherapy in Part 1 of the trial, until disease progression according to RECIST version 1.1, symptomatic deterioration or death from any cause, whichever occurs first. PD could base on symptom deterioration or was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions. Participants were censored at the last tumor assessment. Participants who have no tumor assessments after baseline and who were still alive will be censored at 1 day.
Time frame: Approximately 28 months (assessed at screening and every 9 weeks from randomization until disease progression)
Part 2: Progression-free Survival (PFS) Assessed by the Investigator
PFS (Investigator-assessed) is defined as the time from randomization, until disease progression according to RECIST v1.1 including death or MBO, whichever occurs first. Censoring is based on the last tumor assessment. If no tumor assessment post baseline, then censoring is at day 1. PD could base on symptom deterioration or was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions.
Time frame: Approximately 44 months (assessed at screening and every 9 weeks from randomization until disease progression)
Part 2: European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Questionnaire (QLQ) of Core 30 (C30) Score
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores averaged, transformed to 0-100 scale; for functional scores, a higher score represents a better level of functioning. For symptom scores, a higher score represents a more severe level of symptoms. For the global health status scores, a higher score represents a better quality of life.
Time frame: Baseline (assessed at baseline and every 9 weeks from randomization until disease progression)
Part 2: Percentage of Participants With Adverse Events (AEs)
An AE can be any unfavorable and unintended sign (including an abnormality laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Approximately 28 months (assessed at screening, baseline until 28 days after the last dose of study treatment)
Part 2: Overall Survival
Overall survival was defined as the time from randomization into Part 2 of the trial until death from any cause
Time frame: Approximately 44 months (assessed at screening and every 9 weeks from randomization until disease progression)
| Milestone | Part 1: Pertuzumab + Topotecan | Part 1: Pertuzumab + Paclitaxel | Part 2: Pertuzumab+Chemotherapy | Part 2: Placebo+Chemotherapy |
|---|---|---|---|---|
| Started | 22 | 28 | 0 | 0 |
| Completed | 6 | 5 | 0 | 0 |
| Not completed | 16 | 23 | 0 | 0 |
| Withdrew: Participants withdrawn consent | 1 | 1 | 0 | 0 |
| Withdrew: Death | 15 | 20 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 0 |
| Milestone | Part 1: Pertuzumab + Topotecan | Part 1: Pertuzumab + Paclitaxel | Part 2: Pertuzumab+Chemotherapy | Part 2: Placebo+Chemotherapy |
|---|---|---|---|---|
| Started | 0 | 0 | 78 | 78 |
| Participants randomized but not treated | 0 | 0 | 1 | 2 |
| Participants mis-randomized | 0 | 0 | 2 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 78 | 78 |
| Withdrew: Participant withdrew consent | 0 | 0 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 62 | 68 |
| Withdrew: Alive at data-cut | 0 | 0 | 13 | 7 |
| Withdrew: Participant noncompliance | 0 | 0 | 0 | 1 |
An AE can be any unfavorable and unintended sign (including an abnormality laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| percentage of participants | Part 1: Pertuzumab + Topotecan | Part 1: Pertuzumab + Paclitaxel |
|---|---|---|
| Part 1: Percentage of Participants With Adverse Events (AEs) | 95.5 | 100.0 |
PFS (IRC-Assessed) was defined as the time from randomization into Part 2 of the trial until progressive disease (PD), MBO or death from any cause, whichever occurred first per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. PD could base on symptom deterioration or was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions.
| months | Part 2: Pertuzumab+Chemotherapy | Part 2: Placebo+Chemotherapy |
|---|---|---|
| Part 2: Progression Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Including Malignant Bowel Obstruction (MBO) | 4.27 (3.65 to 6.11) | 2.74 (2.14 to 4.73) |
ORR was defined as the number of participants with best overall response (BOR) of complete response (CR) or partial response (PR) recorded from the start of treatment, until the end of treatment. BOR documented as confirmed CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeter (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Part 1: Pertuzumab + Topotecan | Part 1: Pertuzumab + Paclitaxel |
|---|---|---|
| Part 1- Objective Response Rate (ORR) | 14.3 | 25.0 |
ORR was defined as the number of participants with BOR of CR or PR recorded from the start of treatment, until the end of treatment. BOR documented as confirmed CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeter (mm). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Part 2: Pertuzumab+Chemotherapy | Part 2: Placebo+Chemotherapy |
|---|---|---|
| Part 2- Objective Response Rate (ORR) | 14.8 (7.0 to 26.2) | 8.7 (3.3 to 18.0) |
PFS as assessed by Investigator was defined as the time from first dose of pertuzumab or chemotherapy in Part 1 of the trial, until disease progression according to RECIST version 1.1, symptomatic deterioration or death from any cause, whichever occurs first. PD could base on symptom deterioration or was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions. Participants were censored at the last tumor assessment. Participants who have no tumor assessments after baseline and who were still alive will be censored at 1 day.
| months | Part 1: Pertuzumab + Topotecan | Part 1: Pertuzumab + Paclitaxel |
|---|---|---|
| Part 1: PFS Assessed by the Investigator | 4.07 (1.94 to 6.08) | 4.24 (3.45 to 6.01) |
PFS (Investigator-assessed) is defined as the time from randomization, until disease progression according to RECIST v1.1 including death or MBO, whichever occurs first. Censoring is based on the last tumor assessment. If no tumor assessment post baseline, then censoring is at day 1. PD could base on symptom deterioration or was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions.
| months | Part 2: Pertuzumab+Chemotherapy | Part 2: Placebo+Chemotherapy |
|---|---|---|
| Part 2: Progression-free Survival (PFS) Assessed by the Investigator | 4.22 (3.25 to 5.22) | 3.94 (2.63 to 4.30) |
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores averaged, transformed to 0-100 scale; for functional scores, a higher score represents a better level of functioning. For symptom scores, a higher score represents a more severe level of symptoms. For the global health status scores, a higher score represents a better quality of life.
| units on a scale | Part 2: Pertuzumab+Chemotherapy | Part 2: Placebo+Chemotherapy |
|---|---|---|
| Functional Scales: Physical (n=71, 74) | 71.1 ± 22.77 | 74.9 ± 20.85 |
| Functional Scales: Role (n=70, 73) | 68.6 ± 33.16 | 69.4 ± 32.40 |
| Functional Scales: Emotional (n=71, 73) | 59.5 ± 24.03 | 65.9 ± 23.42 |
| Functional Scales: Cognitive (n=71, 73) | 81.2 ± 25.34 | 84.9 ± 20.25 |
| Functional Scales: Social (n=71, 73) | 70.7 ± 30.01 | 68.3 ± 29.81 |
| Symptomatic Scales: Fatigue (n=71, 74) | 41.2 ± 28.75 | 38.4 ± 27.77 |
| Symptomatic Scales: Nausea and vomiting (n=72, 74) | 10.4 ± 15.68 | 12.4 ± 20.47 |
| Symptomatic Scales: Pain (n=72, 74) | 35.2 ± 31.34 | 31.1 ± 29.24 |
| Symptomatic Scales: Dyspnoea (n=68, 73) | 22.5 ± 28.47 | 21.5 ± 27.98 |
| Symptomatic Scales: Insomnia (n=69, 74) | 35.3 ± 31.25 | 31.5 ± 31.16 |
| Symptomatic Scales: Appetite loss (n=71, 73) | 24.9 ± 30.19 | 21.0 ± 26.36 |
| Symptomatic Scales: Constipation (n=69, 72) | 25.6 ± 32.41 | 26.4 ± 32.59 |
| Symptomatic Scales: Diarrhoea (n=69, 72) | 14.5 ± 26.49 | 14.4 ± 22.26 |
| Symptomatic Scales:Financial difficulties(n=70,72 | 17.6 ± 28.78 | 13.4 ± 22.83 |
| Global health status / QoL scale (n=71, 72) | 54.1 ± 24.99 | 61.1 ± 22.29 |
An AE can be any unfavorable and unintended sign (including an abnormality laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| percentage of participants | Part 2: Pertuzumab+Chemotherapy | Part 2: Placebo+Chemotherapy |
|---|---|---|
| Part 2: Percentage of Participants With Adverse Events (AEs) | 98.7 | 100 |
Overall survival was defined as the time from randomization into Part 2 of the trial until death from any cause
| months | Part 2: Pertuzumab+Chemotherapy | Part 2: Placebo+Chemotherapy |
|---|---|---|
| Part 2: Overall Survival | 10.18 (6.67 to 15.24) | 8.36 (6.14 to 11.99) |
Collected over Approximately 28 months (assessed at screening, baseline until 28 days after the last dose of study treatment). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Pertuzumab + Topotecan | — | 9/22 (40.9%) | 21/22 (95.5%) |
| Part 1: Pertuzumab + Paclitaxel | — | 11/28 (39.3%) | 27/28 (96.4%) |
| Part 2: Pertuzumab+Chemotherapy | — | 29/77 (37.7%) | 72/77 (93.5%) |
| Part 2: Placebo+Chemotherapy | — | 33/76 (43.4%) | 75/76 (98.7%) |
| Event | Part 1: Pertuzumab + Topotecan | Part 1: Pertuzumab + Paclitaxel | Part 2: Pertuzumab+Chemotherapy | Part 2: Placebo+Chemotherapy |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 2/22 | 0/28 | 0/77 | 0/76 |
| Intestinal ObstructionGastrointestinal disorders | 0/22 | 2/28 | 0/77 | 4/76 |
| AnaemiaBlood and lymphatic system disorders | 0/22 | 2/28 | 1/77 | 2/76 |
| PyrexiaGeneral disorders | 0/22 | 2/28 | 1/77 | 2/76 |
| DiarrhoeaGastrointestinal disorders | 1/22 | 0/28 | 4/77 | 0/76 |
| Abdominal PainGastrointestinal disorders | 1/22 | 0/28 | 2/77 | 2/76 |
| NauseaGastrointestinal disorders | 1/22 | 0/28 | 1/77 | 1/76 |
| SubileusGastrointestinal disorders | 1/22 | 0/28 | 3/77 | 1/76 |
| VomitingGastrointestinal disorders | 1/22 | 0/28 | 3/77 | 2/76 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 1/22 | 0/28 | 2/77 | 1/76 |
| Event | Part 1: Pertuzumab + Topotecan | Part 1: Pertuzumab + Paclitaxel | Part 2: Pertuzumab+Chemotherapy | Part 2: Placebo+Chemotherapy |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 14/22 | 22/28 | 50/77 | 23/76 |
| AnaemiaBlood and lymphatic system disorders | 15/22 | 10/28 | 28/77 | 32/76 |
| AstheniaGeneral disorders | 14/22 | 8/28 | 32/77 | 24/76 |
| VomitingGastrointestinal disorders | 13/22 | 5/28 | 19/77 | 23/76 |
| NauseaGastrointestinal disorders | 11/22 | 10/28 | 31/77 | 34/76 |
| Decreased AppetiteMetabolism and nutrition disorders | 8/22 | 5/28 | 13/77 | 17/76 |
| FatigueGeneral disorders | 5/22 | 10/28 | 21/77 | 24/76 |
| AlopeciaSkin and subcutaneous tissue disorders | 7/22 | 10/28 | 15/77 | 21/76 |
| Mucosal InflammationGeneral disorders | 7/22 | 2/28 | 11/77 | 6/76 |
| NeutropeniaBlood and lymphatic system disorders | 5/22 | 3/28 | 23/77 | 21/76 |
Part 1: all participants enrolled and treated in Part 1 of the study ('as treated' analysis) and Part 2: intent-to-treat (ITT) population was defined as all randomized participants in the group to which they were randomly assigned ('as randomized' analysis).
| Age, Customized(participants) | Part 1: Pertuzumab + Topotecan | Part 1: Pertuzumab + Paclitaxel | Part 2: Pertuzumab+Chemotherapy | Part 2: Placebo+Chemotherapy | Total |
|---|---|---|---|---|---|
| Less than or equal to (≤)65 years | 15 | 17 | 40 | 44 | 116 |
| Greater than (>)65 years | 7 | 11 | 38 | 34 | 90 |
| Sex: Female, Male(Participants) | Part 1: Pertuzumab + Topotecan | Part 1: Pertuzumab + Paclitaxel | Part 2: Pertuzumab+Chemotherapy | Part 2: Placebo+Chemotherapy | Total |
|---|---|---|---|---|---|
| Female | 22 | 28 | 78 | 78 | 206 |
| Male | 0 | 0 | 0 | 0 | 0 |
Ran from Oct 2012 to primary completion in Jan 2015, 27 months.
Results were first posted in Nov 2016, 1 year 9 months after primary completion.
Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 27 months is below that.
Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemcitabine · Pertuzumab · Topotecan